The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549 **FORM D** 

## OMB APPROVAL OMB Number: 3235-0076 Estimated average burden

4.00

hours per response:

## **Notice of Exempt Offering of Securities**

1. Issuer's Identity			
	Draviava		
CIK (Filer ID Number)	Previous Names	X None	Entity Type
0001801198			X Corporation
Name of Issuer			Limited Partnership
Legend Biotech Corp			Limited Liability Company
Jurisdiction of Incorporation/Org	ganization		General Partnership
CAYMAN ISLANDS	-		
Year of Incorporation/Organizat	tion		Business Trust
X Over Five Years Ago			Other (Specify)
Within Last Five Years (Spe	ecify Year)		
Yet to Be Formed	,		
2. Principal Place of Business	and Contact Information		
Name of Issuer			
Legend Biotech Corp			
Street Address 1		Street Address 2	
2101 COTTONTAIL LANE		Cit doi: / idd1033 Z	
City	State/Province/Country	ZIP/PostalCode	Phone Number of Issuer
SOMERSET	NEW JERSEY	08873	732-317-5050
OOMEROET	TVEVV VERGET	00075	752 517 5355
3. Related Persons			
Last Name	First Name		Middle Name
Huang, Ph.D.	Ying		
Street Address 1	Street Address 2		
c/o Legend Biotech Corporation	2101 COTTONTA	IL LANE	
City	State/Province/C	ountry	ZIP/PostalCode
SOMERSET	NEW JERSEY		08873
Relationship: X Executive Offi	icer X Director Promoter		
Clarification of Response (if Neo	cessary):		
Last Name	First Name		Middle Name
Macomber	Lori		
Street Address 1	Street Address 2		
c/o Legend Biotech Corporation	2101 COTTONTA	IL LANE	
City	State/Province/Country		ZIP/PostalCode
SOMERSET	NEW JERSEY	÷	08873
Relationship: X Executive Off			
Clarification of Response (if Neo	cessary):		
Last Name	First Name		Middle Name
Zhang, Ph.D.	Fangliang		made Hame
Street Address 1	Street Address 2		
c/o Legend Biotech Corporation	2101 COTTONTA	IL LANE	
City	State/Province/Co		ZIP/PostalCode
SOMERSET	NEW JERSEY	ounity y	08873
			333.5
Relationship: Executive Offi	cer X Director Promoter		

Clarification of Response (if Necessa	ry):		
Last Name	First Name	Middle Name	
Wang, M.S.	Ye		
Street Address 1	Street Address 2		
c/o Legend Biotech Corporation	2101 COTTONTAIL LANE		
City	State/Province/Country	ZIP/PostalCode	
SOMERSET	NEW JERSEY	08873	
Relationship: Executive Officer		33373	
Clarification of Response (if Necessa			
Ciamication of Nesponse (ii Necessar			
Last Name	First Name	Middle Name	
Zhu, Ph.D.	Li		
Street Address 1	Street Address 2		
c/o Legend Biotech Corporation	2101 COTTONTAIL LANE		
City	State/Province/Country	ZIP/PostalCode	
SOMERSET	NEW JERSEY	08873	
Relationship: Executive Officer	Director Promoter		
Clarification of Response (if Necessa	ry):		
Last Name	First Name	Middle Name	
Ji, M.D., Ph.D.	Darren	Xiaohui	
Street Address 1	Street Address 2		
c/o Legend Biotech Corporation	2101 COTTONTAIL LANE		
City	State/Province/Country	ZIP/PostalCode	
SOMERSET	NEW JERSEY	08873	
Relationship: Executive Officer	Director Promoter		
Clarification of Response (if Necessa	ry):		
Last Name	First Name	Middle Name	
Sanders, Ph.D.	Corazon	D.	
Street Address 1	Street Address 2		
c/o Legend Biotech Corporation	2101 COTTONTAIL LANE		
City	State/Province/Country	ZIP/PostalCode	
SOMERSET	NEW JERSEY	08873	
Relationship: Executive Officer X	Director Promoter		
Clarification of Response (if Necessa	ry):		
Last Name	First Name	Middle Name	
Yau, CPA	Philip	Wai Man	
Street Address 1	Street Address 2		
c/o Legend Biotech Corporation	2101 COTTONTAIL LANE		
City	State/Province/Country	ZIP/PostalCode	
SOMERSET	NEW JERSEY	08873	
Relationship: Executive Officer	Director Promoter		
Clarification of Response (if Necessa	ry):		
Last Name	First Name	Middle Name	
Casey, Ph.D.	Patrick	MIGGIE NAITIE	
Street Address 1	Street Address 2		
c/o Legend Biotech Corporation	2101 COTTONTAIL LANE		
City	State/Province/Country	ZIP/PostalCode	
SOMERSET	NEW JERSEY	08873	
_		5557.5	
Relationship: Executive Officer X	Director Promoter		
Clarification of Response (if Necessar	ry):		
Last Name	First Name	Middle Name	

Mao, MD	Li		
Street Address 1	Street Address 2		
c/o Legend Biotech Corporation	2101 COTTONTAIL LANE		
City	State/Province/Country	ZIP/PostalCode	
SOMERSET	NEW JERSEY	08873	
Relationship: Executive Officer X Dir	rector Promoter		
Clarification of Response (if Necessary):			
Last Name	First Name	Middle Name	
Heyman	Tomas		
Street Address 1	Street Address 2		
c/o Legend Biotech Corporation	2101 COTTONTAIL LANE	7ID/DestalCode	
City SOMERSET	State/Province/Country NEW JERSEY	ZIP/PostalCode 08873	
Relationship: Executive Officer X Dir		00073	
Clarification of Response (if Necessary):			
4. Industry Group			
Agriculture	Health Care	Retailing	
Banking & Financial Services	X Biotechnology	Restaurants	
Commercial Banking	Health Insurance	Technology	
Insurance	Hospitals & Physicians	Computers	
Investing			
Investment Banking	Pharmaceuticals —	Telecommunications	
Pooled Investment Fund	Other Health Care	Other Technology	
Is the issuer registered as	Manufacturing	Travel	
an investment company under the Investment Company	Real Estate	Airlines & Airports	
Act of 1940?	Commercial	Lodging & Conventions	
∏Yes ∏No	Construction	Loughing & Conventions	
Other Banking & Financial Service		Tourism & Travel Services	
	REITS & Finance	Other Travel	
Business Services	Residential	Other	
Energy	Other Real Estate	Unici	
Coal Mining			
Electric Utilities			
Energy Conservation			
Environmental Services			
Oil & Gas			
Other Energy			
5. Issuer Size			
Revenue Range OR	Aggregate Net Asset Va	alue Range	
No Revenues	No Aggregate Net A	-	
\$1 - \$1,000,000	\$1 - \$5,000,000		
\$1,000,001 - \$5,000,000	\$5,000,001 - \$25,00	0,000	
\$5,000,001 - \$25,000,000	\$25,000,001 - \$50,0		
\$25,000,001 -	H		
\$100,000,000	\$50,000,001 - \$100,	000,000	
Over \$100,000,000	Over \$100,000,000		
X Decline to Disclose	Decline to Disclose		
Not Applicable	Not Applicable		
6. Federal Exemption(s) and Exclusion	(s) Claimed (select all that apply)		
Rule 504(b)(1) (not (i), (ii) or (iii))	Investment Comp	any Act Section 3(c)	
$\sqcap$			

Rule 504 (b)(1)(ii)  Rule 504 (b)(1)(iii)  X Rule 506(b)  Rule 506(c)  Securities Act Section 4(a)(5)  Section  Section  Section  Section  Section  Section	on 3(c)(1)			
X New Notice Date of First Sale 2023-04-19 First Sale Yes Amendment	t to Occur			
8. Duration of Offering				
Does the Issuer intend this offering to last more than one year?	Yes X No			
9. Type(s) of Securities Offered (select all that apply)				
<ul> <li>X Equity</li> <li>Debt</li> <li>Option, Warrant or Other Right to Acquire Another Security</li> <li>Security to be Acquired Upon Exercise of Option, Warrant or Right to Acquire Security</li> </ul>	Pooled Investment Fund Interests Tenant-in-Common Securities Mineral Property Securities Other Other (describe)			
10. Business Combination Transaction				
Is this offering being made in connection with a business combinenger, acquisition or exchange offer?	nation transaction, such as a Yes X No			
Clarification of Response (if Necessary):				
11. Minimum Investment				
Minimum investment accepted from any outside investor \$0 US	D			
12. Sales Compensation				
Recipient	Recipient CRD Number X None			
(Associated) Broker or Dealer X None	(Associated) Broker or Dealer CRD Number $\overline{\mathbf{X}}$ None			
Street Address 1	Street Address 2			
State(s) of Solicitation (select all that apply)  All States	State/Province/Country  Foreign/non-US	ZIP/Postal Code		
Check "All States" or check individual States				
13. Offering and Sales Amounts				
Total Offering Amount \$200,000,005 USD or Indefinite  Total Amount Sold \$200,000,005 USD  Total Remaining to be Sold \$0 USD or Indefinite				
Clarification of Response (if Necessary):				
The exact Total Offering Amount and Total Amount Sold is US\$200,000,004.16, respectively, each rounded to \$200,000,005 for purposes of reporting on Form D.				
14. Investors				
Select if securities in the offering have been or may be sold enter the number of such non-accredited investors who alre Regardless of whether securities in the offering have been of	ady have invested in the offering.  or may be sold to persons who do not qualify as accredited			
investors, enter the total number of investors who already have invested in the offering:				
15. Sales Commissions & Finder's Fees Expenses				

an estimate and check the box next to the amount.
Sales Commissions \$0 USD  Estimate
Finders' Fees \$0 USD  Estimate
Clarification of Response (if Necessary):
16. Use of Proceeds
Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.
\$0 USD Estimate
Clarification of Response (if Necessary):
Signature and Submission

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

## **Terms of Submission**

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.\*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Legend Biotech Corp	/s/ Lori Macomber	Lori Macomber	Chief Financial Officer	2023-04-28

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

<sup>\*</sup> This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.